I have been renting cars from @SixtUSA lately but I am noticing a scam to get you to buy insurance and assigning scratches that are preexisting to customers who do not buy such insurance. Time to stop using SIXT #rentalcar #rentalcarinsurance
Important paper, value in screening at earlier age with MRI with the caveat of FP results. Breast Cancer Screening Strategies for Women With ATM, CHEK2, and PALB2 Pathogenic Variants ja.ma/3H4lHaI via @JAMAOnc part of @JAMANetwork
Haluk Tezcan retweeted
Updated analysis of EV201 Cohort 2 (cisplatin ineligible mUC pts post IO). Enfortumab vedotin showed a 51% ORR with 22% CR, and mDoR of 13.8mo, which is very reassuring of the benefit of EV in this population. #ASCO21
Zenocutuzumab in tumors with NRG-1 fusion,especially in pancreatic cancers, is promising. Another tissue agnostic target in cancer with an active agent? #nrg1 #ASCO21 #ASCO2021 #zenocutuzumab
Congrats Fabrice, not only a great soccer player!!
Congrats to all my friends @GustaveRoussy !!! Well-deserved @FAndreMD @barlesi @jsoriamd #carolineRobert, but surprised @FAndreMD is not in @ogcnice uniform @webofscience
Haluk Tezcan retweeted
Just Out. FDA Approves FoundationOne®Liquid CDx. Pan-Tumor. Includes blood TMB. Starting August 28. The field is now moving very fast. foundationmedicine.com/press…
Haluk Tezcan retweeted
I’m incredibly proud of our Foundation Medicine team! Receiving FDA-approval on the broadest #LiquidBiopsy test represents a monumental step in providing more advanced #cancer patients with the #genomic insights that can lead to more personalized care.
This quoted post is unavailable.
I am not sure that this is a major step forward-suggests that oral tesetaxel provides benefit in previously taxane exposed patients and may become a new backbone for future studies. Will review the data when published.
Foundation Medicine Acquires Lexent Bio to Expand Liquid Biopsy Platforms genomeweb.com/business-news/…
Our team is passionate about changing the way we understand and treat cancer. We’ve spent years building a platform that, once developed and available, will help guide oncologists to identify patients at higher risk for disease progression, and to make... businesswire.com/news/home/2…
Haluk Tezcan retweeted
After 19 years, I’ve left Stanford. The accumulated gender discrimination and harassment had taken their toll. I shared my story with @kate_selig and @StanfordDaily because I think it is important and hope it will empower others to speak up.
THREAD 1/
stanforddaily.com/2020/06/10…
Haluk Tezcan retweeted
Some great news today for people with advanced #TNBC. Sacituzumab govitecan accelerated FDA approval for later line treatment. Objective response rate 33% and median duration of response of 7.7 months.
This Post is from an account that no longer exists. Learn more
Haluk Tezcan retweeted
all our preventative screening needs are put on hold... scheduling mammographies, colonoscopies, pap smears, psa's anyone? i'm personally not willing to go near any health care facilities unless it's for an emergency. #COVIDー19
Haluk Tezcan retweeted
I’m wondering whether it was already here by that time. Is it not possible to check earlier flu cases? I heard samples are discarded but perhaps when an ab test available, we can check recovered ppl.
This Post is from an account that no longer exists. Learn more
Haluk Tezcan retweeted
In my 7 days on one of our (now 12!) non ICU #COVID19 units, I admitted 58 patients for COVID rule out, of whom 50 tested positive. Two died (DNR), 2 went to hospice, and 5 went to the ICU. That is… not my typical gen med service week. Following, some clinical observations.
Haluk Tezcan retweeted
Don’t miss Nicole Lambert from @lexentbio in the Bronze sponsor workshop: "Monitoring cell-free methylation changes with enzymatic conversion to assess response to cancer treatments." Tuesday, Feb 25th, 3:15-3:30 PM. nebiolabs.com/AGBT20
#RNAseq #AGBT20
An awesome collaboration led by FOCR, we are proud to be a part of this effort.
Very exciting time in #CancerResearch, and @CancerResrch is spearheading a large collaborative study on #liquidbiopsies to understand its role & seek the implementation of #ctDNA as a monitoring tool for treatment response


















